Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaxibotulinumtoxinA for Glabellar Lines (SAKURA-2)
NCT03014635Phase 3Completed
- Sponsor
- Revance Therapeutics
- Start
- Dec 2016
- Primary completion
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of daxibotulinumtoxinA in glabellar lines, sponsored by Revance Therapeutics. Started Dec 2016; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT03014635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014635.